Banque Pictet & Cie Sa Intellia Therapeutics, Inc. Transaction History

Banque Pictet & Cie Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$33.3 - $44.82 $239,726 - $322,659	-7,199 Reduced 31.2%	15,878 $591,000
Q4 2022 Feb 06, 2023	SELL	$33.21 - $62.69 $2.77 Million - $5.23 Million	-83,382 Reduced 78.32%	23,077 $0
Q3 2022 Nov 10, 2022	BUY	$53.92 - $71.7 $1.31 Million - $1.74 Million	24,282 Added 29.55%	106,459 $5.96 Billion
Q2 2022 Aug 08, 2022	BUY	$38.49 - $76.21 $488,361 - $966,952	12,688 Added 18.26%	82,177 $4.25 Million
Q1 2022 May 04, 2022	BUY	$58.27 - $118.99 $517,087 - $1.06 Million	8,874 Added 14.64%	69,489 $5.05 Million
Q4 2021 Feb 02, 2022	BUY	$100.76 - $138.36 $6.11 Million - $8.39 Million	60,615 New	60,615 $7.17 Million

317

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $835M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.